Market Cap 89.89M
Revenue (ttm) 0.00
Net Income (ttm) -4.71M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 277,900
Avg Vol 138,974
Day's Range N/A - N/A
Shares Out 37.61M
Stochastic %K 86%
Beta -0.14
Analysts Sell
Price Target $7.00

Company Profile

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201 for the treatment acu...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 20 7495 2379
Address:
14/15 Conduit St, Floor 4, London, United Kingdom
rp6577
rp6577 Oct. 20 at 6:23 PM
$OKYO $3 is calling GC bought a good chunk last week. He sees the value
0 · Reply
Investing4Knowledge
Investing4Knowledge Oct. 17 at 6:16 PM
$OKYO - expecting a run up here before end of year to new highs. Exciting stuff in the pipeline
0 · Reply
rp6577
rp6577 Oct. 17 at 6:12 PM
$OKYO heating up
0 · Reply
pAmdd
pAmdd Oct. 17 at 3:43 PM
$OKYO how is this even possible
0 · Reply
moosegoose
moosegoose Oct. 17 at 2:08 PM
$OKYO https://www.investing.com/news/sec-filings/okyo-pharma-executive-chairman-linked-entity-acquires-210000-shares-on-nasdaq-93CH-4292296
0 · Reply
Investing4Knowledge
Investing4Knowledge Oct. 8 at 8:16 PM
$OKYO - back to $3 🔜 here 👀
1 · Reply
rp6577
rp6577 Oct. 8 at 2:33 PM
$OKYO 🔥
0 · Reply
WilliamsEmpire
WilliamsEmpire Oct. 7 at 9:00 PM
$OKYO how do we get updates on the 100 person trial?
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 6 at 7:36 PM
$OKYO Excellent article that nails exactly where OKYO stands right now. So if you want to update your OKYO knowledge or get acquainted with OKYO, this is a must read. https://beyondspx.com/quote/OKYO/analysis/okyo-pharma-s-visionary-pivot-unlocking-neuropathic-corneal-pain-s-untapped-potential-nasdaq-okyo
1 · Reply
rp6577
rp6577 Oct. 3 at 2:12 PM
$OKYO strong support at $2
0 · Reply
Latest News on OKYO
OKYO Pharma Announces Chairman and Founder Acquires Shares

Oct 16, 2025, 8:30 AM EDT - 9 days ago

OKYO Pharma Announces Chairman and Founder Acquires Shares


OKYO Pharma Announces Chairman and CEO Acquire Shares

Jan 31, 2025, 7:00 AM EST - 9 months ago

OKYO Pharma Announces Chairman and CEO Acquire Shares


OKYO Pharma CEO Interview to Air on Bloomberg TV

Aug 23, 2024, 9:00 AM EDT - 1 year ago

OKYO Pharma CEO Interview to Air on Bloomberg TV


OKYO Pharma Announces Chairman Acquires Shares

Aug 23, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma Announces Chairman Acquires Shares


OKYO Pharma Limited Announces Withdrawal of Public Offering

Sep 14, 2023, 8:45 AM EDT - 2 years ago

OKYO Pharma Limited Announces Withdrawal of Public Offering


OKYO Pharma Announces Public Offering of Ordinary Shares

Sep 13, 2023, 4:05 PM EDT - 2 years ago

OKYO Pharma Announces Public Offering of Ordinary Shares


OKYO Pharma Limited Receives Nasdaq Deficiency Notice

Jul 28, 2023, 5:05 PM EDT - 2 years ago

OKYO Pharma Limited Receives Nasdaq Deficiency Notice


Notice of General Meeting and Publication of Circular

Apr 5, 2023, 2:00 AM EDT - 2 years ago

Notice of General Meeting and Publication of Circular


Notice of Intention to Delist From The London Stock Exchange

Apr 4, 2023, 2:00 AM EDT - 2 years ago

Notice of Intention to Delist From The London Stock Exchange


OKYO Pharma Today Announces Director Acquires Shares

Mar 30, 2023, 2:01 AM EDT - 2 years ago

OKYO Pharma Today Announces Director Acquires Shares


OKYO Pharma Announces PDMR Dealing

Mar 24, 2023, 3:00 AM EDT - 2 years ago

OKYO Pharma Announces PDMR Dealing


OKYO Pharma Limited Prices $5.3 Million Offering of ADSs

Mar 13, 2023, 4:15 PM EDT - 2 years ago

OKYO Pharma Limited Prices $5.3 Million Offering of ADSs


rp6577
rp6577 Oct. 20 at 6:23 PM
$OKYO $3 is calling GC bought a good chunk last week. He sees the value
0 · Reply
Investing4Knowledge
Investing4Knowledge Oct. 17 at 6:16 PM
$OKYO - expecting a run up here before end of year to new highs. Exciting stuff in the pipeline
0 · Reply
rp6577
rp6577 Oct. 17 at 6:12 PM
$OKYO heating up
0 · Reply
pAmdd
pAmdd Oct. 17 at 3:43 PM
$OKYO how is this even possible
0 · Reply
moosegoose
moosegoose Oct. 17 at 2:08 PM
$OKYO https://www.investing.com/news/sec-filings/okyo-pharma-executive-chairman-linked-entity-acquires-210000-shares-on-nasdaq-93CH-4292296
0 · Reply
Investing4Knowledge
Investing4Knowledge Oct. 8 at 8:16 PM
$OKYO - back to $3 🔜 here 👀
1 · Reply
rp6577
rp6577 Oct. 8 at 2:33 PM
$OKYO 🔥
0 · Reply
WilliamsEmpire
WilliamsEmpire Oct. 7 at 9:00 PM
$OKYO how do we get updates on the 100 person trial?
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 6 at 7:36 PM
$OKYO Excellent article that nails exactly where OKYO stands right now. So if you want to update your OKYO knowledge or get acquainted with OKYO, this is a must read. https://beyondspx.com/quote/OKYO/analysis/okyo-pharma-s-visionary-pivot-unlocking-neuropathic-corneal-pain-s-untapped-potential-nasdaq-okyo
1 · Reply
rp6577
rp6577 Oct. 3 at 2:12 PM
$OKYO strong support at $2
0 · Reply
William_The_Great
William_The_Great Oct. 2 at 8:55 AM
$OKYO when is the next major update? November ?
0 · Reply
William_The_Great
William_The_Great Sep. 29 at 5:45 PM
$OKYO what’s a good time to enter ?
3 · Reply
rp6577
rp6577 Sep. 27 at 3:15 PM
$OKYO with regards the recently announced bed 100 patient trial, it is labeled a "registration pathway" trial. It’s therefore designed to generate the pivotal data needed for NDA submission—effectively serving as a Phase 2/3 hybrid or standalone confirmatory study
0 · Reply
Ventureville
Ventureville Sep. 24 at 4:24 PM
$OKYO Always comes back to execution. $BIOV still has DPX-SurMAGE and HapTenix active, just waiting on the right partners to push faster.
0 · Reply
Vinceofmaui
Vinceofmaui Sep. 24 at 1:50 PM
$PLUG OKYO Pharma Stock Rises After Company Outlines Development Pathway For Neuropathic Corneal Pain Drug $OKYO https://stocktwits.com/news/equity/markets/okyo-pharma-stock-rises-after-company-outlines-development-pathway-for-neuropathic-corneal-pain-drug/chDQvHoR32v
0 · Reply
Oscarca
Oscarca Sep. 23 at 10:28 AM
0 · Reply
StocktwitsNews
StocktwitsNews Sep. 22 at 5:35 PM
OKYO Pharma Stock Rises After Company Outlines Development Pathway For Neuropathic Corneal Pain Drug $OKYO https://stocktwits.com/news/equity/markets/okyo-pharma-stock-rises-after-company-outlines-development-pathway-for-neuropathic-corneal-pain-drug/chDQvHoR32v
0 · Reply
rp6577
rp6577 Sep. 22 at 5:13 PM
$OKYO starting to rally of that bottom $XBI
0 · Reply
Oscarca
Oscarca Sep. 22 at 2:55 PM
$OKYO https://www.globenewswire.com/news-release/2025/09/22/3153922/0/en/OKYO-Pharma-Announces-Registration-Pathway-with-100-Patient-Multi-Center-Clinical-Trial-of-Urcosimod-in-Neuropathic-Corneal-Pain.html?fbclid=IwdGRjcAM-QopleHRuA2FlbQIxMQABHlzQ5mvMCU2xcb8ukxyoCMDS_cK2OhcJJX0IWTO8-tY9HXuKOEkAFzuZ-noi_aem_gMxT8MfLq3KEiklmHpKQZw
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Sep. 22 at 12:39 PM
$OKYO OKYO Pharma Announces Plans For Next Stage Of Clinical Development For Lead Drug Candidate, Urcosimod, To Treat Neuropathic Corneal Pain
0 · Reply
rp6577
rp6577 Sep. 22 at 12:33 PM
$OKYO exactly what we were waiting for! Clear route forward, which is exactly what a big Pharma partner needs
0 · Reply
rp6577
rp6577 Sep. 20 at 9:35 PM
$OKYO could get very interesting from here
0 · Reply